Investment Rating - The report maintains an "Outperform" rating for CSPC Pharmaceutical Group [2][12][23] Core Insights - In 9M25, CSPC achieved revenue of CNY 19.9 billion, a year-on-year decrease of 12%, with finished drug revenue at CNY 15.5 billion, down 17% year-on-year [3][16] - The gross profit margin (GPM) was reported at 65.6%, a decline of 4.9 percentage points year-on-year [3][16] - Management anticipates a return to positive growth in finished drug sales by 2026, despite uncertainties surrounding the renewal rules for generic drug procurement [3][16] Financial Performance Summary - Revenue projections for FY25 and FY26 have been adjusted to CNY 27.3 billion and CNY 30.1 billion, respectively, reflecting slower-than-expected out-licensing income recognition [9][23] - Net profit attributable to shareholders is forecasted at CNY 5.0 billion for FY25 and CNY 5.1 billion for FY26, down from previous estimates [9][23] - The company reported a net profit of CNY 3.5 billion in 9M25, a decrease of 7% year-on-year [3][16] Segment Performance - In 3Q25, all segments of finished drugs showed quarter-on-quarter improvement, with total finished drug revenue reaching CNY 4.7 billion, an increase of 8% quarter-on-quarter [5][18] - Notable revenue contributions in 3Q25 included CNY 1.91 billion from the nervous system segment and CNY 0.32 billion from the respiratory system, which saw a 73% year-on-year increase [21][18] Research and Development - R&D expenses for 9M25 were CNY 4.2 billion, an increase of 8% year-on-year, with an R&D expense ratio of 21.0% [3][16] - The company is advancing multiple clinical pipelines, including SYS6010, with clinical data expected to be released in 2026 [20][22] Out-Licensing Opportunities - The report highlights significant potential for out-licensing multiple assets, including SYS6010, which is progressing well in clinical trials [6][19] - The company's business development strategy is entering a phase of tangible results, with expectations for continuous deals that will enhance net profit [6][19]
石药集团（01093）：9M25业绩回顾：成药各板块收入环比改善，关注管线对外授权机会